These proteins, called E7 proteins, are associated with a high risk of cervical cancer, researchers said.
“Our new urine test can detect HPV16 E7 proteins, which are critical markers of cervical cancer risk, at extremely low levels,” said lead researcher Etsuro Ito, a professor of biology at Waseda University in Japan. “This means that women may be able to screen for cervical cancer without the discomfort and inconvenience of a traditional Pap test.”
It also found the proteins in 71% of women with Stage 2 CIN and 38% of women with Stage 3 CIN, results show.
“We believe that the E7 oncoprotein is critical in the early stages of HPV-related cervical carcinogenesis and E7 may play a more significant role in the progression of CIN1 and CIN2 than in CIN3,” Ito said in a university news release.
The availability of a simple urine test could aid efforts to eradicate cervical cancer by eliminating barriers related to screening, researchers said.
“This new method holds great promise for early detection and prevention of cervical cancer,” Ito said. “We are optimistic that further development and validation of this assay will lead to its widespread use in clinical settings.”
The study was recently published in the journal Microorganisms.
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.